More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This chronic lung ...
Mild to moderate COPD with vs without emphysema is associated with significantly worse HRQOL, but similar lung function decline.
GlobalData on MSN2d
FDA to review GSK’s Nucala for COPDThe US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...
News Medical on MSN7d
COPD patients' perspectives should guide development of new therapiesThe perspectives and priorities of people living with chronic obstructive pulmonary disease (COPD) should be integrated into ...
The perspectives and priorities of people living with chronic obstructive pulmonary disease (COPD) should be integrated into ...
Sunway Medical Centre, Sunway City consultant physician, respiratory medicine and interventional pulmonologist Dr Syed Ajmal Syed Ali said that low awareness is one of Malaysia's biggest challenges in ...
“A chronic cough is often the first symptom which, over time, becomes more persistent,” notes Chaggar. “As COPD progresses, ...
US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...
Comparison measures of lung function and improved categorization of cardiovascular disease (CVD) risk were among the key ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...
In a report released today, Larry Biegelsen from Wells Fargo maintained a Hold rating on Pulmonx (LUNG – Research Report), with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback